If you have been reading about Angiotensin IV analog and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-20. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or lower | For lyophilized powder; avoid repeated freeze-thaw. |
| Appearance | White to off-white powder | Common for lyophilized peptides. |
| Solubility | Soluble in water and aqueous buffers | Limited solubility in nonpolar solvents. |
| Typical analytical method | Reverse-phase HPLC and mass spectrometry | Used for purity and identity checks. |
| Typical purity specification | 95% or greater by HPLC area | Supplier values vary; not a biological potency measure. |
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
=== Ceremony and the role of shamans === Shamans, curanderos and experienced users of ayahuasca advise against consuming ayahuasca when not in the presence of one or several well-trained shamans. In some areas, there are purported brujos (Spanish for "witches") who masquerade as real shamans and who entice tourists to drink ayahuasca in their presence. Shamans believe one of the purposes for this is to steal one's energy and/or power, of which they believe every person has a limited stockpile. The shamans lead the ceremonial consumption of the ayahuasca beverage, in a rite that typically takes place over the entire night. During the ceremony, the effect of the drink lasts for hours. Prior to the ceremony, participants are instructed to abstain from spicy foods, red meat and sex. The ceremony is usually accompanied with purging which include vomiting and diarrhea, which is believed to release built-up emotions and negative energy.
== Media == Ariely has appeared in several documentary films and television productions. In 2011, he worked on the documentary The Flaw, which investigates the causes of the 2008 financial crisis. In it, Ariely explained and presented scientific data on the forces that shape human behavior, motivation, and decision-making. In 2015, Ariely appeared in another documentary, (Dis)Honesty: The Truth About Lies. It explores three key themes: why people lie, how often they do it, and the consequences of dishonest behavior. Ariely contributed to Boom Bust Boom, a 2015 documentary about economic crashes. In 2019, he appeared in The Inventor: Out for Blood in Silicon Valley, a documentary that tracks the rise and fall of Theranos. In 2022, he contributed to Why Like This? Lama Kacha, a Hebrew television series broadcast on Kan 11. In it, Ariely distilled complex scientific concepts and provided accessible explanations for the forces that shape human behavior, motivation, and decision-making. Ariely has also presented talks at several TED, with titles such as "Our Buggy Moral Code" and "Unraveling the Mysteries of Human Behavior".
=== Treatment of alcoholism === Apomorphine was one of the earliest used pharmacotherapies for alcoholism. The Keeley Cure (1870s to 1900) contained apomorphine, among other ingredients, but the first medical reports of its use for more than pure emesis come from James Tompkins and Charles Douglas. Tompkins reported, after injection of 6.5 mg ("one tenth of a grain"):In four minutes free emesis followed, rigidity gave way to relaxation, excitement to somnolence, and without further medication the patient, who before had been wild and delirious, went off into a quiet sleep.Douglas saw two purposes for apomorphine:[it can be used to treat] a paroxysm of dipsomania [an episode of intense alcoholic craving]... in minute doses it is much more rapidly efficient in stilling the dipsomaniac craving than strychnine or atropine… Four or even 3m [minim – roughly 60 microlitres] of the solution usually checks for some hours the incessant demands of the patient… when he awakes from the apomorphine sleep he may still be demanding alcohol, though he is never then so insistent as before. Accordingly it may be necessary to repeat the dose, and even to continue to give it twice or three times a day. Such repeated doses, however, do not require to be so large: 4 or even 3m is usually sufficient.This use of small, continuous doses (1/30th of a grain, or 2.16 mg by Douglas) of apomorphine to reduce alcoholic craving comes some time before Pavlov's discovery and publication of the idea of the "conditioned reflex" in 1903.
=== Transcriptional activities === The shorter p110 CUX1 isoform stably interacts with DNA and can function as transcriptional repressor or activator depending on promoter context. Transcription and cell-based assays demonstrated a role for p110 CUX1 in stimulating cell cycle progression and cell proliferation, strengthening of the spindle assembly checkpoint, ensuring an efficient DNA damage response, promoting cell migration and invasion, and increasing resistance to apoptotic signals. Of note, the p200 CUX1 protein was inactive in all these transcriptional and cell-based assays. p110 CUX1 has been demonstrated to bind the protective allele of FTO single nucleotide polymorphisms (SNPs) rs8050136 or rs1421085 highly associated with human obesity, and promote the expression of RPGRIP1L. RPGRIP1L hypomorphism in mice results in obesity, suggesting an important role of CUX1 in body weight regulation.
Dalton's law of partial pressures An empirical law which states that in a mixture of non-reacting gases, the total pressure exerted by all of the gases combined is equal to the sum of the partial pressures exerted by each gas individually.
Sources: en.wikipedia.org
For services to the community in Hockley Heath, West Midlands. Josephine Parkin. For services to the community in Wakefield, West Yorkshire. Rachel Frances Parkinson. For services to the community in Whitefield, Greater Manchester during Covid-19. Bryony Emily Kate Peall. For services to the community in Saxmundham, Suffolk during Covid-19. Diana Marian Pearman. For services to the community in Sonning Common, Oxfordshire. Michelle Louise Pearse. Quality and Business Support Manager, Nuclear Decommissioning Authority. For services to Education and to the community in West Cumbria. Pearl Ann Pearson-Brooke. For services to the community in Martham, Great Yarmouth, Norfolk. Doreen May Peck. For services to the community in Ashtead, Surrey. Captain (Rtd) Michael Neville Pemberton. Chief Executive Officer, Building Extraordinary Communities. For services to Regeneration and to the community in Cumbria. Michael James Penston. For services to the community in Southampton, Hampshire, during Covid-19. Betty Philipson. President, City Road Club (Hull). For services to Cycling and to the community in the East Riding of Yorkshire. Bryan Phillips. Volunteer, Irish Guards Association. For services to Armed Forces Charities in Northern Ireland. Malson Phillips. Chair, South Wales Shire Horse Society. For services to Conservation. Sukhdev Singh Phull. Engineer, Department for Transport. For services to Transport Technology and for charitable services through the Ekom Charity Trust. Brian Pilgrim. Lately Whitehall Area Workplace Services Manager, Government Property Agency.
== Optical excitation and ionization schemes == Optical ionization schemes are developed to produce element-selective ion source for various elements. Most of the elements of the periodic table have been resonantly ionized by using one of five major optical routes based on the principle of RIMS. The routes were formed by the absorption of two or three photons to achieve excitation and ionization and are provided on the basis of optically possible transitions between atomic levels in a process called the bound-bound transition. For an atom of the element to be promoted to a bound-continuum, the energies emitted from the photons must be within the energy range of the selected tunable lasers. Also, the ionization energy of the last emitted photon must exceed that of the atom. The optical ionization schemes are denoted by the amount of photons necessary to make the ion pair. For the first two Schemes 1 and 2, two photons (and processes) are involved. One photon excites the atom from the ground state to an intermediate state while the second photon ionizes the atom. In Schemes 3 and 4, three photons (and processes) are involved. The first two distinct photons create consecutive bound-bound transitions within the selected atom while the third photon is absorbed for ionization. Scheme 5 is a three-photon two-intermediate-level photoionization process. After the first two photons have been absorbed by the optical energy, the third photon achieves ionization. The RIS process can be used to ionize all elements on the periodic table, except helium and neon, using available lasers.
4-HO-DPT, also known as 4-hydroxy-N,N-dipropyltryptamine or as deprocin, is a psychedelic drug of the tryptamine and 4-hydroxytryptamine families related to psilocin (4-HO-DMT). It is taken orally. The drug acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT2A receptor. It produces psychedelic-like effects in animals. The drug is closely structurally related to other psychedelic tryptamines such as dipropyltryptamine (DPT), 5-MeO-DPT, and psilocin (4-HO-DMT), among others. 4-HO-DPT was first described in the scientific literature by David Repke and colleagues in 1977. It was encountered as a novel designer drug in 2012. A presumed prodrug, 4-AcO-DPT, is also known, and has likewise been encountered as a designer drug.
=== July === 1 July – Dennis Lattimer, muralist (born 1946). 2 July – Des Gorman, diving and hyperbaric medicine specialist (University of Auckland) and health bureaucrat (born 1953). 3 July Terry Brown, brothel owner (born 1956/1957). (death announced on this date) Hilary Stace, disability and autism advocate, eugenics researcher (born 1954) 5 July – Tim Bray, actor, comedian, and children's theatre founder (born 1964). 6 July – Kay Bradford, child and adolescent psychiatrist (born 1930). 9 July – Bruce Harris, legal academic (University of Otago, University of Auckland). 11 July Bert Brownlie, economist (University of Auckland, University of Canterbury) and university administrator, University of Canterbury vice-chancellor (1977–1998) (born 1932). Alex McNabb, mathematician (DSIR), Fellow of the Royal Society of New Zealand (since 1985) (born 1930). 12 July – Heather Roe, field hockey player (national team) (born 1939). 15 July – Neill Price, firefighter, local politician and community leader, Waimakariri District Councillor (1989–1998) (born 1936). 16 July Chris Faiumu, musician (Fat Freddy's Drop) and reggae-dub producer. Bruce McTavish, boxing referee (born 1940). Andrew Oliver, oldest person known to have survived with Fryns–Aftimos syndrome (born c. 1984). 17 July Barrie Downey, business executive (Fletcher Challenge) (born 1930). Don McIntosh, rugby union player (Wellington, national team) (born 1931). Greer Twiss, sculptor (Karangahape Rocks) and educator (University of Auckland), Arts Foundation of New Zealand Icon (since 2011) (born 1937).
Transmembrane ATPases import metabolites necessary for cell metabolism and export toxins, wastes, and solutes that can hinder cellular processes. An important example is the sodium-potassium pump (Na+/K+ATPase) that maintains the cell membrane potential. Another example is the hydrogen potassium ATPase (H+/K+ATPase or gastric proton pump) that acidifies the contents of the stomach. ATPase is genetically conserved in animals; therefore, cardenolides which are toxic steroids produced by plants that act on ATPases, make general and effective animal toxins that act dose dependently. Besides exchangers, other categories of transmembrane ATPase include co-transporters and pumps (however, some exchangers are also pumps). Some of these, like the Na+/K+ATPase, cause a net flow of charge, but others do not. These are called electrogenic transporters and electroneutral transporters, respectively. Genetic variants in ATPases result in a wide spectrum of human diseases, from prenatal to later onset disease.
Sources: en.wikipedia.org
The lyophilized powder is commonly kept at -20 °C or lower, protected from moisture and light. Solutions may require colder storage and should avoid repeated freeze-thaw cycles. General peptide stability practices apply.
Reverse-phase HPLC can estimate purity, while mass spectrometry helps confirm molecular mass. These methods do not prove biological effects. Lot-specific certificates may provide additional data.
It is not an approved medicine in major jurisdictions. Depending on the country and marketing claims, it may be treated as a research chemical or unapproved substance. Import and sale rules vary.
Typical storage is at -20 °C in a desiccated container protected from light. Repeated freeze-thaw cycles are usually minimized to reduce degradation. Specific conditions should follow the supplier’s documentation.